SURGE IN AUTISM DRUG DEMAND TESTS DOCTORS AMID SPARSE EVIDENCE
What happens when the hope for the future of the child meets the grinding process of medical science? This is the question that is currently being answered at the pediatric clinics that are demanding massive supplies of the prescription form of folate known as leucovorin following the announcement by former President Donald Trump that it is the breakthrough for the treatment of autism. Leucovorin is already approved by the FDA for treating excessive levels of the amino acid homocyst
Since September, children’s physician Kristin Sohl has had her office flooded with calls from concerned moms and dads. Some of them come with determination, having done their homework, printing out papers from the internet in support of their claims. But Sohl’s message to most of them is no. While some initial clinical trials have suggested benefit, in improving communication and cognitive skills, for example, in some children, the trials have been conducted on a handful of subjects, not enough to put her or them on firm ground yet, Sohl explains to them.
The increase in demand is putting pressure on practitioners who are used to being guided by straightforward, evidence-supported recommendations, Turnacioglu explained in an interview. Children’s National Hospital in Washington, D.C. consulted with specialists in caring for people with autism, genetics, psychiatry, and primary care to reach a consensus on a position. Let’s wait until there is more credible evidence to start recommending it, they agreed. “Gosh I hope there will be something to the drug and it will help people in the future, but the data is simply not there yet.” said Dr. Peter Crino, Chairman of Neurology at the School of Medicine in College Park, University of Maryland. However, quite honestly, there is no concrete evidence.
Leucovorin has a long medical lineage that goes back several decades in cancer treatment, where it safeguards normal cells from specific chemotherapies and enhances the potency of other drugs. Adverse reactions in cancer patients have been very mild: nausea and fatigue. Its relevance in autism studies comes from a biological hack: children with autism produce antibodies that inhibit the entry of folate into their brains. Leucovorin, as a form of folinic acid, uses a different pathway across the blood-brain barrier.
Such a mechanism finds proof through growing science. A double-blinded, placebo-controlled clinical trial conducted in India demonstrated that autism symptoms showed greater improvement in children taking folinic acid compared to the placebo group. This was most marked in autism patients who were positive for high titers of folate receptor autoantibodies. Additionally, no adverse reactions were observed. Such antibodies have reportedly been discovered in 70% of patients suffering from autism spectrum disorder in various reviews. Folinic acid showed improvements in speech, language, and social interactions in such patients.
Nevertheless, there is really big medicine between being hopeful about small studies and rolling out a drug across the country. Larger studies – of a kind that could affirm effectiveness and safety – are still under way. The American Academy of Pediatrics and the Society for Developmental and Behavioral Pediatrics recommend against using the vaccine, but recommend “shared decision-making with families” if they insist, so they can be informed about current evidence.
For families living under such conditions of uncertainty, researchers recommend that all decisions be centered on credible findings and accurate expectations. The findings of studies regarding unusual and newly developed treatment methods have demonstrated the need for persistence and communication between the treatment providers and patients. According to uncertainty management theory, self-belief and trust between the patient and doctor can help avert conditions of frustration and distrust when there are no clear answers.Parents are advised to seek primary findings of studies and assess if improvement has any practical application in everyday life.
Such was also true of Sohl’s own practice. Following months of playing it safe, she finally agreed to try this treatment approach on a patient she had been seeing for a decade – minimally speaking, thoroughly knowledgeable about “the research,” and dedicated to tracking his responses. “I have low expectations, his mom has low expectations, he has low expectations. But we all agreed it was worth a therapeutic trial,” she said.
But now days, the data on leucovorin is reaching a wide range of people quicker in social media than in a scientific journal. This speed can create a multiplier for anxiety and immediacy as well. When scientific data receives a boost due to political approval with a bypass on traditional scientific scrutiny, it can create a situation for healthcare providers where a wait should occur prior to reaching a choice. This is how experts with rare disease experience treat a new unfamiliar disease.
As parents themselves, the way ahead might mean resisting the urge to succumb to the temptations of social claims until the scientific community catches up. In the meantime, a keen eye out for monitoring and communication will play an important role in ensuring that hope is kept safe.
2025-12-16T10:41:29Z